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OBJECTIVE—Cerebral microvascular disease associated with
type 2 diabetes may exacerbate the effects of aging on cognitive
function. A considerable homology exists between the retinal
and cerebral microcirculations; a hypothesized association be-
tween diabetic retinopathy (DR) and cognitive decline was
examined in older people with type 2 diabetes.
RESEARCH DESIGN AND METHODS—In the population-
based Edinburgh Type 2 Diabetes Study, 1,046 men and women
aged 60–75 years with type 2 diabetes underwent standard
seven-ﬁeld binocular digital retinal photography and a battery of
seven cognitive function tests. A general cognitive ability score
(g) was generated by principal components analysis. The Mill-
Hill Vocabulary Scale was used to estimate premorbid cognitive
ability. DR was graded using a modiﬁcation of the Early Treat-
ment of Diabetic Retinopathy Scale.
RESULTS—After age and sex adjustment, a signiﬁcant relation-
ship was observed with increasing severity of DR (none, mild,
and moderate to severe) for most cognitive measures. Partici-
pants with moderate-to-severe retinopathy had the worst g and
the worst performances on the individual tests. There was a
signiﬁcant interaction between sex and retinopathy for g. In male
subjects, the associations of retinopathy with g (and with tests of
verbal ﬂuency, mental ﬂexibility, and processing speed but not
memory and nonverbal reasoning) persisted (P  0.05) when
further adjusted for vocabulary (to estimate lifetime cognitive
decline), depression, sociodemographic characteristics, cardio-
vascular risk factors, and macrovascular disease.
CONCLUSIONS—DR was independently associated with esti-
mated lifetime cognitive decline in older men with type 2
diabetes, supporting the hypothesis that cerebral microvascular
disease may contribute to their observed accelerated age-related
cognitive decline. A sex interaction with stronger ﬁndings in men
requires further conﬁrmation. Diabetes 59:2883–2889, 2010
T
ype 2 diabetes is associated with an increased
risk of age-related cognitive impairment and
decline in addition to higher incidences of stroke
and dementia (1–3). Relatively little is known
about the risk factors associated with the deleterious
effects of type 2 diabetes on accelerated cognitive aging,
although cerebral microvascular disease may be important
(4–6). However, direct in vivo evaluation of the cerebral
microcirculation is difﬁcult and the vessels themselves are
too small to permit detailed visualization with current
neuroimaging methods.
Retinal and cerebral small vessels share similar embry-
ological origin, size, structure, and physiological charac-
teristics (including the blood-brain and blood-retinal
barrier) (7,8). The retinal vascular bed can be directly
visualized noninvasively with retinal photography. Typical
retinopathic changes associated with diabetes are associ-
ated with white matter lesions in the brain, magnetic
resonance imaging (MRI)-deﬁned cerebral infarcts, and
incident stroke (9–11). We hypothesized that increasing
severity of diabetic retinopathy (DR) would be associated
with poorer cognitive ability and with greater cognitive
decline, thus providing evidence for an effect of cerebral
microvascular disease on accelerated age-related cogni-
tive decline in people with type 2 diabetes. Previous
studies have found a signiﬁcant association between the
presence of microaneurysms and reduced performance on
measures of ﬂuid intelligence, processing speed, and at-
tention ability in young adults with type 1 diabetes (12)
and between retinopathy and risk of cognitive impairment
and decline in the general population (13–15), but to our
knowledge the relationship between DR and cognition in
older people with type 2 diabetes has not been examined.
The aim of the present investigation was to determine
the association of DR with both cognitive ability and
estimated lifetime cognitive decline in a large, well-char-
acterized sample of men and women aged 60–75 years
with type 2 diabetes (the Edinburgh Type 2 Diabetes Study
[ET2DS]). Cognitive function was measured using a bat-
tery of neuropsychological tests assessing major cognitive
domains, and cognitive decline was estimated by using a
test of vocabulary to adjust for premorbid cognitive
function.
RESEARCH DESIGN AND METHODS
The ET2DS is a population-based cohort study designed to investigate potentially
modiﬁable risk factors for cognitive decrements in type 2 diabetes. The study
commenced in 2006/2007 as a cross-sectional survey of 547 men and 519 women
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age bands, from the Lothian Diabetes Register, which is a computerized database
containing clinical details on over 20,000 patients with known type 2 diabetes
living in Lothian, Scotland. The Lothian Research Ethics Committee approved the
study, and fully informed written consent was obtained from each participant.
Details of the study recruitment and examination procedures have previously
been described in detail (16). Study participants have been shown to be
representative of the target population of older men and women with type 2
diabetes living in the general population (17).
Cognitive assessment. Specially trained research assistants administered a
detailed battery of cognitive tests in a standard order during a single session in a
quiet and well-lit room following tests for adequate visual acuity and capillary
blood glucose levels (4.0 mmol/l). Cognitive ability was assessed using tests of
immediate and delayed nonverbal memory and verbal declarative memory (Faces
and Family Pictures Subtest [FACES] and Logical Memory I (LM) from the
Wechsler Memory Scale-III
U.K. [18]); nonverbal reasoning, working memory,
information processing speed (Matrix Reasoning [MR], Letter-Number Sequenc-
ing [LNS], and Digit Symbol Test [DST] from the Wechsler Adult Intelligence
Scale 3rd Edition [19]); executive function (Borkowski Verbal Fluency Test [VFT]
[20]) and mental ﬂexibility (Trail Making Test-Part B [TMTB] [21]). Vocabulary
(“crystallized” intelligence) was measured using the combined version of the
Junior and Senior Form A synonyms of the Mill Hill Vocabulary Scale [MHVS]
(22). As results on vocabulary-based tests vary little with aging, they can be used
to estimate peak prior cognitive ability (23,24). Late-life cognition adjusted for
vocabulary correlates highly with actual cognitive change (25). The Mini-Mental
State Examination (MMSE) is often used as a screening for dementia and was
included as a general mental assessment for possible cognitive pathology (26).
Depressed mood was assessed using the Hospital Anxiety and Depression Scale
(27).
Physical examination. A self-administered questionnaire was used to collect
data on age, sex, educational attainment, diabetes history and treatment modality,
smoking history, alcohol consumption, medication use, and history of cardiovas-
cular disease, including the World Health Organization (WHO) Chest Pain (28)
and Edinburgh Claudication (29) questionnaires. Clinical measurements included
plasma A1C and fasting total and HDL serum cholesterol, height, weight, waist
and hip circumferences, a resting 12-lead electrocardiogram, and brachial blood
pressures as previously described (16). Additional information on macrovascular
disease was obtained from the Information and Services Division of NHS
Scotland on all medical and surgical discharges from Scottish hospitals since 1981
(SMR01 scheme), and any K09 or K010 codes indicating cardiovascular or
cerebrovascular disease were extracted.
Retinal photography and grading. Retinal photography was performed
approximately 2–3 weeks after each subject’s initial visit to the research clinic
for cognitive and physiological testing. Of the 1,046 participants who under-
went both cognitive and retinal examinations, two were excluded who did not
have gradable photographs for DR severity in either eye, leaving 1,044 who
provided data for this analysis. After pupillary dilatation, standard seven-ﬁeld
nonstereoscopic color photographs were taken of both eyes at 35° using a
high-resolution digital retinal camera. All photographs were graded by two
trained optometrists, working independently and according to the scale
described by the Early Treatment Diabetic Retinopathy Study (ETDRS)
research group (30). Inter- and intraobserver variations and the validity of this
grading system have previously been evaluated (31). For each eye, the
maximum grade in any of the seven photographic ﬁelds was determined for
each of the characteristic lesions of DR and was used in deﬁning the ﬁnal
retinopathy levels, varying from level 10 (no retinopathy) to level 81 (ad-
vanced proliferative retinopathy). For the purpose of this study, a score of 81
was added for panretinal photocoagulation scars only if the laser treatment
was for DR. The retinopathy level for a participant was assigned on the basis
of the severity scores of the worse eye. If the photographs from an eye could
not be graded, the scores for the other eye were used. Discrepancies in the
ﬁnal level score at subject level between the graders were resolved in the ﬁrst
instance by discussion between them. Unresolved discrepancies were further
reviewed and arbitrated by an ophthalmologist.
Data analyses. Smoking status was deﬁned as current, former, or never. The
average weekly alcohol intake was deﬁned as standard drinks per week (32).
Duration of diabetes was estimated from the age at diagnosis. Diabetes
treatment was classiﬁed into three groups: 1) diet control only, 2) oral
antidiabetes agents without insulin, and 3) insulin injection with or without
oral agents. Waist-to-hip ratio (WHR) was calculated as the waist circumfer-
ence divided by the hip circumference in centimeters. BMI was deﬁned as
weight in kilograms divided by the square of height in meters. Hypercholes-
terolemia was deﬁned as serum total cholesterol 5 mmol/l or use of
medication prescribed by a doctor to lower blood lipids level. Hypertension
was deﬁned as systolic blood pressure 140 mmHg or diastolic blood
pressure 85 mmHg or use of medication prescribed by a doctor to lower
blood pressure. Coronary heart disease (myocardial infarction and/or angina)
was deﬁned if two of the ﬁrst three of the following criteria were met or if both
the ﬁrst and last criteria were met: 1) subject recall of a doctor’s diagnosis of
myocardial infarction or angina, 2) positive WHO chest pain questionnaire, 3)
electrocardiogram evidence of ischemia, and 4) prior hospital discharge (ICD)
code for ischemic heart disease. Cerebrovascular disease (stroke and/or
transient ischemic attack [TIA]) was deﬁned if two of three of the following
criteria were met: 1) subject recall of a doctor’s diagnosis of stroke or TIA, 2)
prior hospital discharge code consistent with stroke or TIA, and 3) conﬁrma-
tion by clinical notes review. Intermittent claudication was based on a positive
response to the Edinburgh Claudication Questionnaire. Any macrovascular
disease was deﬁned as a history of myocardial infarction, angina, stroke, TIA,
or peripheral arterial disease. DR was deﬁned as an ETDRS level of 20, i.e.,
the presence of microaneurysms alone or with any of the following lesions:
hemorrhages, cotton wool spots, intraretinal microvascular abnormalities,
hard exudates, venous beading, venous loops and/or reduplication, ﬁbrous
proliferations, preretinal hemorrhage, vitreous hemorrhage, and new vessels.
This was further divided into mild nonproliferative DR (NPDR) (levels 20–35),
moderate-to-severe NPDR (levels 43–53), and proliferative DR (levels 61–81).
Due to small numbers in the proliferative retinopathy group, severity of DR
was collapsed into three categories (none, mild, and moderate–severe); the
two most severe categories were combined into moderate–severe DR and
used in all subsequent analyses. A measure of general cognitive ability,
representing the variance common to all the cognitive tests except MHVS, was
generated. This was done by subjecting the seven cognitive tests (FACES, LM,
MR, LNS, DST, VFT, and TMTB) to a principal-components analysis. Scree
slope analysis and the eigenvalues-greater-than-1 rule both indicated a single
component (which accounted for 44% of the total variance, on which all tests
had high loadings), thus validating the use of a general factor. Scores on this
ﬁrst unrotated principal component were saved as standardized scores
(mean  SD 0  1).
All continuous variables were normally distributed except for the TMTB
for which a natural logarithmic transformation of scores was used, as
well as depression scores (normalized through a n  1 logarithmic
transformation), duration of diabetes, and alcohol intake (square root
transformations).
Three categories of DR (none, mild, and moderate–severe) were compared
on all demographic and medical variables using tests of linearity included in
ANOVA for continuous data and 
2 analyses for categorical data. ANCOVA
was used for comparing cognitive test scores in subjects according to severity
of DR and in assessing the effects of retinopathy severity on the imputed
cognitive change from estimated peak prior cognitive function (MHVS scores)
at the same time as adjusting for possible confounders. Adjustment variables
were introduced into the models in three cumulative steps. In the ﬁrst step,
age and sex were entered into all models. Then MHVS was entered to obtain
an estimate of cognitive change. Finally, education level, vascular risk factors
(alcohol intake, smoking status, WHR, systolic blood pressure, and total
cholesterol), the presence of macrovascular disease, and depression symp-
toms were additionally adjusted. These variables were selected as possible
confounders if they showed a signiﬁcant association with DR on univariate
analysis or if, in previous literature, a variable was reported to be associated
with both DR and cognitive test performance. We did not include duration of
diabetes or A1C in the main multivariate model because it is likely that
prolonged exposure to hyperglycemia underlies the development of DR and
their inclusion in the model could result in overadjustment. Interactions
between DR and other covariates were also assessed. All tests were two
tailed, and a two-sided P value 0.05 was taken to indicate statistical
signiﬁcance. 
2 values were used to convey effect sizes. All analyses were
performed using SPSS, version 14.0, for Windows (33).
RESULTS
Characteristics of the total ET2DS population (n  1,066)
and comparisons with nonparticipants from the target
population have previously been presented (17). A total of
1,044 subjects had retinal photographs available for grad-
ing. These subjects did not differ signiﬁcantly from sub-
jects without photographs either available or suitable for
grading (n  22) with respect to diabetes duration or
treatment, mean A1C, cardiovascular risk factors, or prev-
alence of macrovascular disease (data not shown). How-
ever, they did perform signiﬁcantly better on tests of
nonverbal memory (mean  SD FACES scores 66.0  7.8
vs. 58.3  7.0; P  0.001), verbal declarative memory
(mean LM scores 25.4  8.2 vs. 20.0  5.9; P  0.003), and
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0.53  0.77; P  0.014).
Of the 1,044 type 2 diabetic participants, 339 (32.5%)
subjects had any DR. Of these, 292 (86.1%) had mild NPDR,
32 (9.4%) had moderate-to-severe NPDR, and 15 (4.4%) had
proliferative retinopathy (n  19 and n  8 for men in the
latter two categories, respectively). A comparison of char-
acteristics according to DR severity is given in Table 1.
Subjects with DR were more likely to be receiving insulin
treatment and had higher mean A1C, diabetes duration,
and WHR. They also had a higher prevalence of previous
stroke/TIA.
In the total study population, age- and sex-adjusted
general cognitive ability (g) was signiﬁcantly lower in the
group with moderate-to-severe DR (mean 0.44 [95% CI
0.73 to 0.16]) compared with the group without DR
(0.05 [0.03 to 0.12]; P  0.003), with an intermediate
score for the mild DR group (0.04 [0.17 to 0.07]) (P for
trend  0.003). No signiﬁcant associations were found
between DR and estimated premobid cognitive ability
(MHVS score). The association between DR and current
general cognitive ability (g) remained statistically signiﬁ-
cant after adjustment for MHVS, but in this model there
was a signiﬁcant interaction between sex and retinopathy
for g (P  0.030). Men appeared to be more affected by
severity of retinopathy than women (Fig. 1). The total
study population was stratiﬁed by sex, and the effects of
retinopathy on g and individual cognitive tests were ex-
amined separately for men and women (Table 2). Follow-
ing age adjustment, signiﬁcant associations were only
found in men between DR and g, VFT and TMTB, and in
both sexes with DST. When adjusted for MHVS to estimate
lifetime change in cognitive ability, the retinopathy-DST
association lost statistical signiﬁcance in women but re-
mained signiﬁcant in men. When further adjusted for a
wide range of potentially confounding variables, including
macrovascular disease, associations in men persisted be-
tween DR and g (P for trend 0.001; 
2  0.020), VFT (P
for trend  0.001; 
2  0.020), TMTB (P for trend  0.009;

2  0.012), and DST (P for trend  0.001; 
2  0.032)
tests (assessing executive function, mental ﬂexibility, and
processing speed, respectively). No statistically signiﬁcant
differences across any of the retinopathy categories were
found for the LM, MR, or LNS tests for either sex. There
was not any signiﬁcant interaction of retinopathy and any
of the variables other than sex.
Analyses were repeated after excluding individuals with
prevalent stroke or history of TIA and those with MMSE
TABLE 1
Characteristics of study participants according to severity of DR
No DR Mild DR
Moderate-to-severe
DR P for trend
n 705 292 47
Mean age (years) 67.3  4.2 67.4  4.2 67.1  4.2 0.962
Male sex 49.2 (347) 55.1 (161) 57.4 (27) 0.061
Education level
University 16 (113) 16.1 (47) 19.1 (9) 0.312
Other profession/technical qualiﬁcation 27.2 (192) 32.9 (96) 25.5 (12)
Secondary/primary school 56.7 (400) 51.0 (149) 55.3 (26)
Diabetes-related variables
Median diabetes duration (years) 5.5 (3.4–9.4) 9.3 (5.1–14.4) 17.1 (12.1–22.9) <0.001
Treatment
Diets 23.8 (168) 9.2 (27) 2.1 (1) <0.001
Oral antidiabetes agents only 65.7 (463) 63.4 (185) 38.3 (18)
Insulin with or without oral
antidiabetes agents 10.5 (74) 27.4 (80) 59.6 (28)
A1C (%) 7.3  1.1 7.5  1.1 8.4  1.4 <0.001
Vascular risk factors
BMI (kg/m
2) 31.4  5.5 31.3  6.1 32.3  5.3 0.521
WHR 0.96  0.07 0.97  0.08 0.99  0.09 0.001
Smoking status
Never 38.0 (268) 39.4 (115) 53.2 (25) 0.112
Former 47.4 (334) 47.6 (139) 36.2 (17)
Current 14.6 (103) 13.0 (38) 10.6 (5)
Median average alcohol intake
(drinks/week) 1 (0–7) 0.6 (0–6.8) 1 (0–3.8) 0.291
Systolic blood pressure (mmHg) 133.3  15.8 133.41  7.4 132.8  19.9 0.972
Hypertension 84.3 (594) 84.6 (247) 95.7 (45) 0.152
Total cholesterol (mmol/l) 4.3  0.9 4.2  0.9 4.3  1.0 0.201
HDL cholesterol (mmol/l) 1.30  0.4 1.29  0.4 1.17  0.4 0.083
Hypercholesterolemia 89.9 (634) 88.4 (258) 100.0 (47) 0.382
Cardiovascular disease variables
Myocardial infarction and/or angina 30.2 (213) 31.5 (92) 44.7 (21) 0.111
Stroke and/or TIA 6.2 (44) 13.4 (39) 14.9 (7) <0.001
Intermittent claudication 5.5 (39) 6.5 (19) 8.5 (4) 0.353
Any macrovascular disease (myocardial
infarction, angina, stroke, TIA, or IC) 35.3 (249) 38.4 (112) 51.1 (24) 0.046
Data are means  SD, % (n), or median (interquartile range) unless otherwise indicated. TIA, transient ischemic attack. Bold values are
statistically signiﬁcant values (P  0.05). IC, intermittent claudication.
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tially altered by these exclusions (data not shown). In a ﬁnal
analysis, associations were also adjusted for A1C and dura-
tion of diabetes. Adjustment for both attenuated the associ-
ation between DR and TMTB to borderline signiﬁcance (P 
0.059) in men but did not change other results.
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FIG. 1. Estimated mean (2 SE) of general factor (g) scores of men and women according to severity of DR.
TABLE 2
Multivariable-adjusted mean (SE) of cognitive scores by severity of DR in men and women
Men Women
No DR Mild DR
Moderate-
to-severe
DR
P for
trend
Effect
of
DR* No DR Mild DR
Moderate-
to-severe
DR
P for
trend
Effect
of
DR*
n 347 161 27 — 358 131 20 —
Age adjusted
VFT 38.0 (0.7) 36.0 (1.0) 31.5 (2.5) 0.006 36.8 (0.7) 36.6 (1.1) 36.9 (2.9) 0.965
FACES 65.0 (0.4) 64.1 (0.6) 62.4 (1.4) 0.052 67.6 (0.4) 67.5 (0.7) 64.8 (1.8) 0.277
Ln (TMTB) 4.68 (0.02) 4.70 (0.03) 4.94 (0.08) 0.013 4.65 (0.02) 4.68 (0.04) 4.82 (0.09) 0.126
DST 48.2 (0.7) 45.8 (1.1) 36.8 (2.7) <0.001 52.4 (0.8) 51.1 (1.3) 44.3 (3.3) 0.037
LM 24.8 (0.4) 24.2 (0.6) 23.8 (1.5) 0.400 26.1 (0.4) 26.8 (0.7) 23.2 (1.9) 0.711
MR 13.4 (0.3) 14.0 (0.4) 12.2 (1.0) 0.971 12.0 (0.3) 12.3 (0.5) 14.3 (1.2) 0.106
LNS 9.8 (0.2) 9.8 (0.2) 9.0 (0.6) 0.473 9.6 (0.1) 9.6 (0.2) 9.2 (0.6) 0.599
g 0.01 (0.05) 0.10 (0.08) 0.63 (0.19) 0.003 0.08 (0.05) 0.03 (0.09) 0.24 (0.23) 0.222
MHVS 31.1 (0.3) 32.0 (0.4) 31.2 (1.0) 0.245 30.7 (0.3) 30.3 (0.4) 29.0 (1.1) 0.138
Age and MHVS adjusted
VFT 38.4 (0.6) 35.5 (0.9) 31.7 (2.3) <0.001 36.6 (0.6) 36.9 (1.0) 38.7 (2.5) 0.533
FACES 65.1 (0.4) 63.9 (0.6) 62.4 (1.4) 0.016 67.5 (0.4) 67.6 (0.7) 65.6 (1.7) 0.512
Ln (TMTB) 4.67 (0.02) 4.71 (0.03) 4.93 (0.07) 0.002 4.65 (0.02) 4.67 (0.03) 4.77 (0.08) 0.268
DST 48.5 (0.7) 45.4 (1.0 37.0 (2.4) <0.001 52.4 (0.7) 51.3 (1.2) 46.1 (3.0) 0.072
LM 24.9 (0.4) 23.8 (0.6) 23.9 (1.4) 0.148 26.0 (0.4) 27.0 (0.7) 24.4 (1.7) 0.723
MR 13.5 (0.2) 13.7 (0.4) 12.3 (0.9) 0.584 12.0 (0.3) 12.3 (0.4) 14.9 (1.0) 0.052
LNS 9.9 (0.1) 9.7 (0.2) 9.1 (0.5) 0.185 9.6 (0.1) 9.7 (0.2) 9.5 (0.5) 0.934
g 0.04 (0.04) 0.15 (0.06) 0.61 (0.15) <0.001 0.05 (0.04) 0.07 (0.07) 0.05 (0.18) 0.828
Fully adjusted†
VFT 38.4 (0.7) 35.5 (1.0) 32.0 (2.4) 0.001 0.020 37.0 (0.7) 37.3 (1.0) 39.8 (2.6) 0.417 0.001
FACES 65.1 (0.4) 64.1 (0.6) 63.2 (1.5) 0.062 0.006 67.6 (0.4) 67.8 (0.7) 66.2 (1.7) 0.811 0.000
Ln (TMTB) 4.67 (0.02) 4.71 (0.03) 4.91 (0.08) 0.009 0.012 4.66 (0.02) 4.67 (0.04) 4.74 (0.09) 0.364 0.002
DST 49.0 (0.7) 45.6 (1.0) 38.8 (2.6) 0.001 0.032 52.4 (0.8) 50.8 (1.2) 46.6 (3.1) 0.060 0.006
LM 24.7 (0.5) 23.8 (0.6) 24.0 (1.5) 0.236 0.002 26.1 (0.5) 26.9 (0.7) 24.5 (1.7) 0.857 0.000
MR 13.5 (0.3) 13.8 (0.4) 12.6 (0.9) 0.857 0.000 12.1 (0.3) 12.5 (0.5) 14.7 (1.1) 0.056 0.006
LNS 9.8 (0.2) 9.7 (0.2) 9.5 (0.5) 0.481 0.001 9.6 (0.1) 9.7 (0.3) 9.6 (0.6) 0.907 0.000
g 0.04 (0.05) 0.14 (0.07) 0.49 (0.15) <0.001 0.020 0.07 (0.05) 0.08 (0.07) 0.02 (0.18) 0.919 0.000
†Further adjusted for education, alcohol intake, smoking status, WHR, systolic blood pressure, total cholesterol, major macrovascular
disease, and depression symptoms. *Effect size of DR as indexed by 2 (the proportion of variance) in the fully adjusted model. Bold values
are statistically signiﬁcant values (P  0.05).
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In this representative population of older people with type
2 diabetes, increasing severity of DR was associated with
poorer general cognitive ability. When analyzed separately
by sex, a signiﬁcant dose-response relationship was found
only in men and for individual tests of verbal ﬂuency,
information processing speed, and mental ﬂexibility (but
not memory and nonverbal reasoning). These associations
persisted after adjustment for estimated premorbid cogni-
tive ability (vocabulary scores), suggesting that in men, DR
was not only associated with cognitive ability in later life
but also with increased estimated lifetime cognitive de-
cline. To estimate cognitive decline, it was not possible to
adjust for the same cognitive test applied at an earlier age,
but all the nonvocabulary tests were signiﬁcantly corre-
lated and vocabulary scores were strongly loaded on
general cognitive ability (coefﬁcient 0.57; P  0.001). After
additional control for education, vascular risk factors,
macrovascular disease, and mood, associations between
DR and estimated cognitive decline remained signiﬁcant,
suggesting that they were not simply due to confounding
by other vascular mechanisms.
To our knowledge, no previous studies have speciﬁcally
examined the relationship between DR and cognitive
functioning in a large group of older people with type 2
diabetes from the general population using comprehensive
and detailed assessment of retinal signs. Two previous
studies did not show an association between DR and
cognitive function in older diabetic patients (34,35), but
these were based on either a direct ophthalmoscopic
examination of the retina or a single-ﬁeld retinal photo-
graph. These methods image only a small portion of the
retina and with considerably less rigor compared with
multiple-ﬁeld photographs and as a result, the prevalence
of DR signs may have been underestimated. Our ﬁndings
are consistent with those from studies of predominantly
nondiabetic older subjects from the general population. In
the Blue Mountains Eye Study (14), subjects with hyper-
tension aged 49 years and older who had evidence of
retinopathy signs were signiﬁcantly more likely to score
poorly (23) on the MMSE, and in the Cardiovascular
Health Study there was a signiﬁcant association between
retinopathy and worse performance on information-pro-
cessing speed in subjects aged 69 years (36). The Ath-
erosclerosis Risk in Communities Study (ARIC) also
reported that retinopathy was independently associated
with poorer cognitive function in middle-aged people free
of stroke (37), both in those with and in those without
diabetes and hypertension. Longitudinal ﬁndings from the
14-year follow-up of the same cohort showed that people
with retinopathy had a greater 10-year decline in verbal
ﬂuency and information-processing speed (but not in
delayed verbal memory) compared with those without
retinal microvascular abnormalities (15).
Due to the considerable homology between retinal and
cerebral microvasculature, retinal vascular changes are
likely to provide an indirect marker of concomitant
changes in the brain microvasculature. It is possible that
accelerated cognitive aging associated with type 2 diabe-
tes may arise, at least in part, from the cumulative impact
of a disruption of blood-brain barrier and/or the ischemic
injuries leading to diverse changes in brain parenchyma.
As our ﬁndings persisted after subjects with recognized
clinical stroke were excluded, perivascular brain damage
and/or ischemia from asymptomatic cerebral small vessel
disease (SVD) could explain the cognitive associations.
For example, microinfarcts and MRI signs of cerebral SVD
(e.g., lacunar infarcts and white matter lesions) have been
shown to contribute importantly to cognitive impairment
and vascular dementia (38–41). Furthermore, increased
blood-brain barrier permeability has been demonstrated in
people with type 2 diabetes (4), and alteration in the
blood-brain barrier secondary to microvascular endothe-
lial dysfunction may be an important pathophysiological
mechanism in the initiation or worsening of cerebral SVD
(42). Cerebral SVD predominantly affects the subcortical
associative areas of deep gray matter (the basal ganglia
and thalamus) and white matter structures, with disrup-
tion of integrity of frontal subcortical circuits. This may
lead to deﬁcits in executive functioning and information
processing. Our results in type 2 diabetes are consistent
with a cognitive proﬁle that is associated with cerebral
SVD.
A striking ﬁnding of the present study was a signiﬁcant
interaction of DR with sex such that the negative associ-
ations of DR with several cognitive measures were statis-
tically signiﬁcant only in men. This difference was not
anticipated a priori. To our knowledge, no previous study
has examined whether sex modiﬁes the relation of reti-
nopathy with cognition. The sex-speciﬁc effect of DR on
cognitive functioning could be inﬂuenced by lower preva-
lence of DR (29.7 vs. 35.1%; P  0.058), coronary heart
disease (24.4 vs. 37.8%; P  0.001); and stroke and/or TIA
(5.5 vs. 11.6%; P  0.001) in women compared with men,
but adjusting for macrovascular disease did not alter the
sex-speciﬁc effects. It is also possible that other unknown
risk factors that were not examined in this analysis (e.g.,
subclinical atherosclerosis, estrogen use, or physical ac-
tivity) could play a mediating role. Although several hy-
potheses have been proposed in an attempt to explain sex
difference observed in some studies, including male-fe-
male differences in brain reserve and differential suscep-
tibility to normal or pathological age-associated changes,
there is no clear empirical evidence on the effect of sex on
cognition in the general population or in people with
diabetes.
Despite the representativeness of our study participants
to the target population in terms of demographic and
clinical characteristics, the possibility of participation
and/or survival bias cannot be completely ruled out.
Indeed, it has been hypothesized that diabetes may be a
more potent risk factor for cognitive dysfunction in
women than in men due to a higher risk of diabetes-related
macrovascular disease and early loss of possible protec-
tive effects of estrogen (due to earlier menopause) on
cognitive functioning (43). It is possible that women with
more severe diabetes (those more likely to have retinop-
athy and cognitive decline) may have died of macrovascu-
lar disease before they could be recruited into the study,
thereby leading to conservative estimates of associations
between retinopathy and cognitive decline. However, the
degree of variation of g scores in men and women in the
study population was similar and, as shown in Table 1,
people with any retinopathy were only slightly more likely
to be male. It therefore seems unlikely that survival bias
could be the full explanation for the sex difference. Given
that we had no speciﬁc a priori reason for assuming that
our association of DR with cognition would be different
between males and females, and given that other studies
have not suggested the existence of such a sex difference,
interpretation of the interaction between sex and DR must
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large studies.
One of the main strengths of this study was the use of
high-quality retinal photographs and detailed grading of
DR using full seven-ﬁeld photography and the low amount
of missing retinal grading data. Other strengths included
the application of a detailed cognitive test battery covering
the major cognitive domains, although use of a single test
to assess each particular cognitive domain could mean
that only limited aspects of what may be considered
complex mental functions were actually determined (20).
The study population had a veriﬁed clinical diagnosis of
type 2 diabetes and has been shown to be representative of
the target population of elderly men and women with the
full range of severity of type 2 diabetes living in the general
population.
The use of a general cognitive factor, g, helped avoid
potential problems caused by multiple testing and residual
confounding by peak prior mental ability was minimized
by controlling for performance on a test of vocabulary
rather than relying solely on level of education as in many
previous studies. Extensive phenotyping for potential con-
founding factors also enabled a comprehensive multivari-
ate analysis. However, the presence of microvascular
complications other than retinopathy in the no DR group
(e.g., neuropathy and nephropathy), leading to shared
microvascular risk burden between the retinopathy and
retinopathy-free subjects, may have tended to reduce
differences toward the null.
The effect size for retinopathy in these older men with
type 2 diabetes was small after multivariate adjustment.
Such a small effect size for risk factors associated with
cognitive decline is not uncommon, including the effects of
other potentially important factors (e.g., apolipoprotein E
genotype and smoking) (44,45). It is possible that even
very modest effects of a risk factor may lead to larger
cognitive deﬁcits and possibly dementia with further ag-
ing. Furthermore, reduction of such a risk factor could
have a signiﬁcant impact on cognition in the diabetic
population as a whole by producing a positive shift in the
overall population distribution of cognitive ability. How-
ever, while our ﬁndings support the hypothesis that reduc-
tion of microvascular disease might reduce the rate of
cognitive decline, the clinical signiﬁcance of our ﬁndings
remains to be established. The major limitation of the
study is that analyses were cross-sectional, with measures
of retinal and cognitive function made almost simulta-
neously, limiting our ability to determine whether DR
preceded or occurred in parallel with cognitive decline.
Prospective studies are required to clarify the temporal
sequence of these associations. Such a follow-up project
involving the present study population for the actual
cognitive change is underway.
In conclusion, DR was independently associated with
estimated lifetime cognitive decline in older men with type
2 diabetes, supporting the hypothesis that cerebral micro-
vascular disease may contribute to the accelerated age-
related cognitive decline observed in diabetic populations.
If the above ﬁndings are substantiated, diabetes-associ-
ated cognitive dysfunction may be amenable to therapeu-
tic and preventive strategies that are targeted speciﬁcally
at protecting the cerebral microvasculature and reducing
the risk of developing even mild microvascular disease in
an aging diabetic population.
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